Clinical features and diagnostic tools in idiopathic inflammatory myopathies

References

• Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5(2):109–129.
   PubMedGoogle Scholar
• Lundberg IE, Miller FW, Tjärnlund A, et al. Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med. 2016;280(1):39–51.
   PubMed Web of Science ®Google Scholar
• Rothwell S, Chinoy H, Lamb JA. Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis. Curr Opin Rheumatol. 2019;31(6):611–616.
   PubMed Web of Science ®Google Scholar
• Gupta L, Naveen R, Gaur P, et al. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. Semin Arthritis Rheum. 2021;51(1):113–120.
   PubMed Web of Science ®Google Scholar
• van de Vlekkert J, Hoogendijk JE, de Visser M. Myositis with endomysial cell invasion indicates inclusion body myositis even if other criteria are not fulfilled. Neuromuscul Disord. 2015;25(6):451–456.
   PubMed Web of Science ®Google Scholar
• van der Meulen MFG, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology. 2003;61(3):316–321.
   PubMed Web of Science ®Google Scholar
• Tanboon J, Nishino I. Classification of idiopathic inflammatory myopathies: pathology perspectives. Curr Opin Neurol. 2019;32(5):704–714.
   PubMed Web of Science ®Google Scholar
• Bohan A. History and classification of polymyositis and dermatomyositis. Clin Dermatol. 1988;6(2):3–8.
   PubMed Web of Science ®Google Scholar
• Medsger TA, Dawson WN, Masi AT. The epidemiology of polymyositis. Am J Med. 1970;48(6):715–723.
   PubMed Web of Science ®Google Scholar
• Devere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain. 1975;98(4):637–666.
   PubMedGoogle Scholar
• Bohan A, Peter JB. Polymyositis and Dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–347.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and Dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–407.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325(21):1487–1498.
   PubMed Web of Science ®Google Scholar
• Targoff IN, Miller FW, Medsger TA, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9(6):527–535.
   PubMedGoogle Scholar
• Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am. 2002;28(4):723–741.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–982.
   PubMed Web of Science ®Google Scholar
• Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337–345.
   PubMedGoogle Scholar
• Lackner A, Tiefenthaler V, Mirzayeva J, et al. The use and diagnostic value of testing myositis-specific and myositis-associated autoantibodies by line immuno-assay: a retrospective study. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975907.
   PubMed Web of Science ®Google Scholar
• del Grande F, Carrino JA, del Grande M, et al. Magnetic resonance imaging of inflammatory myopathies. Top Magn Reson Imaging. 2011;22(2):39–43.
   PubMedGoogle Scholar
• Kristofoor EL, Jemima A. Muscle ultrasound in inflammatory myopathies: a critical review. J Rheum Dis Treat. 2019;5:69.
   Google Scholar
• Bottai M, Tjärnlund A, Santoni G, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017;3(2):e000507.
   PubMed Web of Science ®Google Scholar
• Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955–1964.
   PubMed Web of Science ®Google Scholar
• Maheswaranathan M, Johannemann A, Weiner JJ, et al. Real world utilization of the myositis autoantibody panel. Clin Rheumatol. 2021;40(8):3195–3205.
   PubMed Web of Science ®Google Scholar
• Wong VTL, So H, Lam TTO, et al. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies. Acta Neurol Scand. 2021;143(2):131–139.
   PubMed Web of Science ®Google Scholar
• Lundberg IE, Tjärnlund A. Response to: “2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why? by Malaviya ?”. Ann Rheum Dis. 2018;77(11):e78.
   PubMed Web of Science ®Google Scholar
• Vulsteke J-B, de Langhe E, Claeys KG, et al. Detection of myositis-specific antibodies. Ann Rheum Dis. 2019;78(1):e7.
   PubMed Web of Science ®Google Scholar
• To F, Ventín-Rodríguez C, Elkhalifa S, et al. Line blot immunoassays in idiopathic inflammatory myopathies: Retrospective review of diagnostic accuracy and factors predicting true positive results. BMC Rheumatol. 2020;4:28.
   PubMedGoogle Scholar
• Damoiseaux J, Vulsteke JB, Tseng CW, et al. Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by Mono- and multispecific immunoassays. Autoimmun Rev. 2019;18(3):293–305.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. Acta Myol. 2020;39(4):289–301.
   PubMedGoogle Scholar
• Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018;77(1):30–39.
   PubMed Web of Science ®Google Scholar
• Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008;70(6):418–424.
   PubMed Web of Science ®Google Scholar
• Vilela VS, Prieto-González S, Milisenda JC, et al. Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-up. Rheumatol Int. 2015;35(5):915–920.
   PubMed Web of Science ®Google Scholar
• Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology. 2003;61(3):288–290.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res. 2015;67(7):891–897.
   Web of Science ®Google Scholar
• Milisenda JC, Selva-O’Callaghan A, Grau JM. The diagnosis and classification of polymyositis. J Autoimmun. 2014;48–49:118–121.
   PubMed Web of Science ®Google Scholar
• Lu Z, Guo-Chun W, Li M, et al. Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review. Clin Cardiol. 2012;35(11):685–691.
   Web of Science ®Google Scholar
• Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2000;12(6):501–508.
   PubMed Web of Science ®Google Scholar
• Volochayev R, Csako G, Wesley R, et al. Laboratory test abnormalities are common in polymyositis and dermatomyositis and differ among clinical and demographic groups. Open Rheumatol J. 2012;6:54–63.
   PubMedGoogle Scholar
• Paganoni S, Amato A. Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am. 2013;24(1):193–207.
   PubMed Web of Science ®Google Scholar
• Streib EW, Wilbourn AJ, Mitsumoto H. Spontaneous electrical muscle fiber activity in polymyositis and dermatomyositis. Muscle Nerve. 1979;2(1):14–18.
   PubMed Web of Science ®Google Scholar
• Wilbourn AJ. The electrodiagnostic examination with myopathies. J Clin Neurophysiol. 1993;10(2):132–148.
   PubMed Web of Science ®Google Scholar
• Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2009;80(10):1060–1068.
   PubMed Web of Science ®Google Scholar
• Minetto MA, Lanfranco F, Motta G, et al. Steroid myopathy: some unresolved issues. J Endocrinol Invest. 2011;34(5):370–375.
   PubMed Web of Science ®Google Scholar
• Theodorou DJ, Theodorou SJ, Kakitsubata Y. Skeletal muscle disease: patterns of MRI appearances. Br J Radiol. 2012;85(1020):e1298–e1308.
   PubMed Web of Science ®Google Scholar
• May DA, Disler DG, Jones EA, et al. Abnormal signal intensity in skeletal muscle at MR imaging: patterns, pearls, and pitfalls. Radiographics. 2000;20(suppl_1):S295–S315.
   PubMedGoogle Scholar
• Rosow LK, Amato AA. The role of electrodiagnostic testing, imaging, and muscle biopsy in the investigation of muscle disease. Contin Lifelong Learn Neurol. 2016;22(6):1787–1802.
   Google Scholar
• Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011;7(6):343–354.
   PubMed Web of Science ®Google Scholar
• Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol. 2016;29(5):662–673.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018;28(6):913–921.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147(4):391–398.
   PubMedGoogle Scholar
• Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986;314(6):329–334.
   PubMed Web of Science ®Google Scholar
• Nadin T, Haque A, Akil M, et al. Management of the idiopathic inflammatory myopathies. Prescriber. 2019;30(5):28–33.
   Google Scholar
• Kaltsonoudis E, Pelechas E, Drosos AA. Dermatomyositis sine myositis – case presentation. Mediterr J Rheumatol. 2017;28(1):57–58.
   PubMedGoogle Scholar
• Pinard J, Femia AN, Roman M, et al. Systemic treatment for clinically amyopathic dermatomyositis at 4 tertiary care centers. JAMA Dermatol. 2019;155(4):494–496.
   PubMed Web of Science ®Google Scholar
• Amato AA, Greenberg SA. Inflammatory myopathies. Continuum. 2013;19(6):1615–1633.
   PubMedGoogle Scholar
• Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20(3):387–408.
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis. 2017;76(4):681–687.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am. 2002;28(4):779–798.
   PubMed Web of Science ®Google Scholar
• Bronner IM, Hoogendijk JE, Veldman H, et al. Tubuloreticular structures in different types of myositis: implications for pathogenesis. Ultrastruct Pathol. 2008;32(4):123–126.
   PubMed Web of Science ®Google Scholar
• Uruha A, Nishikawa A, Tsuburaya RS, et al. Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology. 2017;88(5):493–500.
   PubMed Web of Science ®Google Scholar
• Suárez-Calvet X, Gallardo E, Pinal-Fernandez I, et al. RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis. Arthritis Res Ther. 2017;19(1):174.
   PubMedGoogle Scholar
• Smith ES, Hallman JR, Deluca AM, et al. Dermatomyositis: a clinicopathological study of 40 patients. Am J Dermatopathol. 2009;31(1):61–67.
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, et al. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol. 2015;42(8):1448–1454.
   PubMed Web of Science ®Google Scholar
• Ghirardello A, Zampieri S, Iaccarino L, et al. Anti-Mi-2 antibodies. Autoimmunity. 2005;38(1):79–83.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013;65(11):2954–2962.
   PubMed Web of Science ®Google Scholar
• Albayda J, Pinal-Fernandez I, Huang W, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res. 2017;69(11):1771–1776.
   PubMed Web of Science ®Google Scholar
• Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva OA, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and Meta-analysis. Arthritis Rheum. 2012;64(2):523–532.
   PubMed Web of Science ®Google Scholar
• Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep. 2017;7(1):188.
   PubMedGoogle Scholar
• Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, et al. Anti-MDA5 antibodies in a large mediterranean population of adults with dermatomyositis. J Immunol Res. 2014;2014:290797.
   PubMed Web of Science ®Google Scholar
• Narang NS, Casciola-Rosen L, Li S, et al. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res. 2015;67(5):667–672.
   PubMed Web of Science ®Google Scholar
• Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–2200.
   PubMed Web of Science ®Google Scholar
• Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78(4):776–785.
   PubMed Web of Science ®Google Scholar
• Hodgkinson LM, Wu TT, Fiorentino DF. Dermatomyositis autoantibodies: how can we maximize utility? Ann Transl Med. 2021;9(5):433–433.
   PubMed Web of Science ®Google Scholar
• Zampeli E, Venetsanopoulou A, Argyropoulou OD, et al. Myositis autoantibody profiles and their clinical associations in greek patients with inflammatory myopathies. Clin Rheumatol. 2019;38(1):125–132.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–678.
   PubMed Web of Science ®Google Scholar
• Argobi Y, Smith GP. Tracking changes in nailfold capillaries during dermatomyositis treatment. J Am Acad Dermatol. 2019;81(1):275–276.
   PubMed Web of Science ®Google Scholar
• Vermaak E, Tansley SL, McHugh NJ. The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review. Clin Rheumatol. 2015;34(12):2089–2095.
   PubMed Web of Science ®Google Scholar
• Tiffreau V, Kopciuch F, Thevenon A, et al. Functionnal improvement with a rehabilitation programme in dermatmyositis an polymyositis: results of a randomized controlled trial. Ann Phys Rehabil Med. 2016;59:e81–e82.
   Google Scholar
• Mendez EP, Lipton R, Ramsey-Goldman R, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the national institute of arthritis and musculoskeletal and skin diseases registry. Arthritis Rheum. 2003;49(3):300–305.
   PubMed Web of Science ®Google Scholar
• Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine. 2013;92(4):223–243.
   PubMed Web of Science ®Google Scholar
• Iwata N, Nakaseko H, Kohagura T, et al. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: experience at a single center in Japan. Mod Rheumatol. 2019;29(5):802–807.
   PubMed Web of Science ®Google Scholar
• Deakin CT, Yasin SA, Simou S, et al. Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. Arthritis Rheumatol. 2016;68(11):2806–2816.
   PubMed Web of Science ®Google Scholar
• Qiang JK, Kim WB, Baibergenova A, et al. Risk of malignancy in dermatomyositis and polymyositis: a systematic review and Meta-analysis. J Cutan Med Surg. 2017;21(2):131–136.
   PubMed Web of Science ®Google Scholar
• Brady S. Inclusion body myositis. Curated Ref Collect Neurosci Biobehav Psychol. 2016;2016:240–248.
   Google Scholar
• Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve. 2000;23(6):970–972.
   PubMed Web of Science ®Google Scholar
• Molberg Ø, Dobloug C. Epidemiology of sporadic inclusion body myositis. Curr Opin Rheumatol. 2016;28(6):657–660.
   PubMed Web of Science ®Google Scholar
• Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in The Netherlands: a nationwide study. Neurology. 2000;55(9):1385–1387.
   PubMed Web of Science ®Google Scholar
• Bradshaw EM, Orihuela A, McArdel SL, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol. 2007;178(1):547–556.
   PubMed Web of Science ®Google Scholar
• Mastaglia FL, Needham M, Scott A, et al. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Disord. 2009;19(11):763–765.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010;10(3):346–352.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006;2(8):437–447.
   PubMedGoogle Scholar
• Dalakas MC. Pathophysiology of inflammatory and autoimmune myopathies. Presse Med. 2011;40(4 Pt 2):e237–e247.
   PubMedGoogle Scholar
• Greenberg SA. Inclusion body myositis. Contin Lifelong Learn Neurol. 2016;22(6):1871–1888.
   Google Scholar
• Weihl CC. Sporadic inclusion body myositis and other rimmed vacuolar myopathies. Contin Lifelong Learn Neurol. 2019;25(6):1586–1598.
   Google Scholar
• Badrising UA, Maat-Schieman MLC, van Houwelingen JC, et al. Inclusion body myositis: clinical features and clinical course of the disease in 64 patients. J Neurol. 2005;252(12):1448–1454.
   PubMed Web of Science ®Google Scholar
• Riminton DS, Chambers ST, Parkin PJ, et al. Inclusion body myositis presenting solely as dysphagia. Neurology. 1993;43(6):1241–1243.
   PubMed Web of Science ®Google Scholar
• Wintzen AR, Bots GTAM, de Bakker HM, et al. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry. 1988;51(12):1542–1545.
   PubMed Web of Science ®Google Scholar
• Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134(Pt 11):3167–3175.
   PubMedGoogle Scholar
• Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(11):3176–3184.
   PubMedGoogle Scholar
• Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry. 2013;84(11):1240–1246.
   PubMed Web of Science ®Google Scholar
• Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014;83(5):426–433.
   PubMed Web of Science ®Google Scholar
• Hilton-Jones D, Brady S. Diagnostic criteria for inclusion body myositis. J Intern Med. 2016;280(1):52–62.
   PubMed Web of Science ®Google Scholar
• Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38(5):705–713.
   PubMed Web of Science ®Google Scholar
• Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve. 1998;21(1):115–117.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Gallardo E, et al. Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol. 1997;41(1):100–104.
   PubMed Web of Science ®Google Scholar
• Cupler EJ, Leon-Monzon M, Miller J, et al. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain. 1996;119(6):1887–1893.
   PubMedGoogle Scholar
• Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology. 2006;66(2 Suppl 1):S33–S38.
   PubMedGoogle Scholar
• Beck EH, Amato AA, Greenberg SA. Inclusion body myositis and chronic lymphocytic leukemia: a case series. Neurology. 2014;83(1):98–99.
   PubMed Web of Science ®Google Scholar
• Pluk H, van Hoeve BJA, van Dooren SHJ, et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73(3):397–407.
   PubMed Web of Science ®Google Scholar
• Goyal NA, Cash TM, Alam U, et al. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J Neurol Neurosurg Psychiatry. 2016;87(4):373–378.
   PubMed Web of Science ®Google Scholar
• Benjamin Larman H, Salajegheh M, Nazareno R, et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73(3):408–418.
   PubMed Web of Science ®Google Scholar
• Kula RW, Sawchak JA, Sher JH. Inclusion body myositis. Curr Opin Rheumatol. 1989;1(4):460–467.
   PubMedGoogle Scholar
• Cox FM, Reijnierse M, van Rijswijk CSP, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology. 2011;50(6):1153–1161.
   PubMed Web of Science ®Google Scholar
• Leeuwenberg KE, van Alfen N, Christopher-Stine L, et al. Ultrasound can differentiate inclusion body myositis from disease mimics. Muscle Nerve. 2020;61(6):783–788.
   PubMed Web of Science ®Google Scholar
• Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol. 1984;16(2):209–215.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Sahenk Z, Gales T, et al. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol. 1991;48(12):1229–1234.
   PubMedGoogle Scholar
• Hiniker A, Daniels BH, Lee HS, et al. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun. 2013;1(1):29.
   PubMed Web of Science ®Google Scholar
• Lindgren U, Roos S, Hedberg Oldfors C, et al. Mitochondrial pathology in inclusion body myositis. Neuromuscul Disord. 2015;25(4):281–288.
   PubMed Web of Science ®Google Scholar
• Needham M, Mastaglia FL. Sporadic inclusion body myositis: a review of recent clinical advances and current approaches to diagnosis and treatment. Clin Neurophysiol. 2016;127(3):1764–1773.
   PubMed Web of Science ®Google Scholar
• Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology. 1995;45(7):1302–1304.
   PubMed Web of Science ®Google Scholar
• Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82(4):441–447.
   PubMed Web of Science ®Google Scholar
• Darrow DH, Hoffman HT, Barnes GJ, et al. Management of dysphagia in inclusion body myositis. Arch Otolaryngol Head Neck Surg. 1992;118(3):313–317.
   PubMedGoogle Scholar
• Cohen MR, Sulaiman AR, Garancis JC, et al. Clinical heterogeneity and treatment response in inclusion body myositis. Arthritis Rheum. 1989;32(6):734–740.
   PubMedGoogle Scholar
• Yongchairat K, Tanboon J, Waisayarat J, et al. Clinical spectrums and outcomes of necrotizing autoimmune myopathy versus other idiopathic inflammatory myopathies: a multicenter case-control study. Clin Rheumatol. 2019;38(12):3459–3469.
   PubMed Web of Science ®Google Scholar
• Christopher-Stine L, Plotz PH. Inflammatory muscle diseases. Clin Immunol. 2008;373(4):825–835.
   Google Scholar
• Kassardjian CD, Lennon VA, Alfugham NB, et al. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol. 2015;72(9):996–1003.
   PubMed Web of Science ®Google Scholar
• Day JA, Limaye V. Immune-mediated necrotising myopathy: a critical review of current concepts. Semin Arthritis Rheum. 2019;49(3):420–429.
   PubMed Web of Science ®Google Scholar
• Musset L, Allenbach Y, Benveniste O, et al. Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study. Autoimmun Rev. 2016;15(10):983–993.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Benveniste O, Stenzel W, et al. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689–701.
   PubMed Web of Science ®Google Scholar
• Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64(12):4087–4093.
   PubMed Web of Science ®Google Scholar
• Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 2011;63(7):1961–1971.
   PubMed Web of Science ®Google Scholar
• Arouche-Delaperche L, Allenbach Y, Amelin D, et al. Pathogenic role of anti–signal recognition protein and anti–3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol. 2017;81(4):538–548.
   PubMed Web of Science ®Google Scholar
• Rojana-Udomsart A, Mitrpant C, Bundell C, et al. Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM). J Neuroimmunol. 2013;264(1–2):65–70.
   PubMed Web of Science ®Google Scholar
• Bergua C, Chiavelli H, Allenbach Y, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis. 2019;78(1):131–139.
   PubMed Web of Science ®Google Scholar
• Tiniakou E, Pinal-Fernandez I, Lloyd TE, et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutarylcoenzyme a reductase-associated autoimmune myopathy. Rheumatol. 2017;56:787–794.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord. 2018;28(1):87–99.
   PubMed Web of Science ®Google Scholar
• Basharat P, Lahouti AH, Paik JJ, et al. Statin-induced anti-HMGCR-associated myopathy. J Am Coll Cardiol. 2016;68(2):234–235.
   PubMed Web of Science ®Google Scholar
• Klein M, Mann H, Pleštilová L, et al. Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. Rheumatology. 2015;54(11):2010–2014.
   PubMed Web of Science ®Google Scholar
• Kadoya M, Hida A, Maeda MH, et al. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm. 2016;3(6):e290.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016;139(Pt 8):2131–2135.
   PubMedGoogle Scholar
• Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20(4):21.
   PubMed Web of Science ®Google Scholar
• Lim J, Rietveld A, de Bleecker JL, et al. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurol Neuroimmunol Neuroinflamm. 2019;6(1):e513.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016;87(10):1038–1044.
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Parks C, Werner JL, et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition Particle. Arthritis Care Res. 2017;69(2):263–270.
   Web of Science ®Google Scholar
• Landon-Cardinal O, Koumako C, Hardouin G, et al. Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI. Semin Arthritis Rheum. 2020;50(6):1437–1440.
   PubMed Web of Science ®Google Scholar
• Opinc AH, Makowska JS. Antisynthetase syndrome – much more than just a myopathy. Semin Arthritis Rheum. 2021;51(1):72–83.
   PubMed Web of Science ®Google Scholar
• Masiak A, Marzec M, Kulczycka J, et al. The clinical phenotype associated with antisynthetase autoantibodies. Reumatologia. 2020;58(1):4–8.
   PubMedGoogle Scholar
• Ghirardello A, Bassi N, Palma L, et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep. 2013;15(6):335.
   PubMed Web of Science ®Google Scholar
• Ceribelli A, Isailovic N, De Santis M, et al. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol. 2017;36(2):469–475.
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology. 2017;56(6):999–1007.
   PubMed Web of Science ®Google Scholar
• L’Angiocola PD, Mattei L, Lardieri G. A misdiagnosed case of antisynthetase syndrome complicated by myocarditis: when the cardiologist deals with rheumatology. Clin Rheumatol. 2019;38(8):2275–2280.
   PubMed Web of Science ®Google Scholar
• Gorecka MM, Tummon O, Smyth Y. When your immune system falls out with your heart: an important lesson on antisynthetase myocarditis. BMJ Case Rep. 2018;2018:bcr2018226019.
   PubMedGoogle Scholar
• Dieval C, Deligny C, Meyer A, et al. Myocarditis in patients with antisynthetase syndrome: prevalence, presentation, and outcomes. Medicine. 2015;94(26):e798–5.
   PubMed Web of Science ®Google Scholar
• Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011;37(1):100–109.
   PubMed Web of Science ®Google Scholar
• Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies: What progress has been made in the past 35 years? Chest. 2010;138(6):1464–1474.
   PubMed Web of Science ®Google Scholar
• Baccaro ACCD, Pinto GLB, Carboni RCS, et al. The clinical manifestations at the onset of antisynthetase syndrome: a chameleon with multiple faces. Reumatismo. 2020;72(2):86–92.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73(1):227–232.
   PubMed Web of Science ®Google Scholar
• Cavagna L, Nuño L, Scirè CA, et al. Clinical spectrum time course in anti jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study. Medicine. 2015;94(32):e1144–7.
   PubMed Web of Science ®Google Scholar
• Noguchi E, Uruha A, Suzuki S, et al. Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol. 2017;74(8):992–999.
   PubMed Web of Science ®Google Scholar
• Vulsteke JB, Satoh M, Malyavantham K, et al. Anti-OJ autoantibodies: rare or underdetected? Autoimmun Rev. 2019;18(7):658–664.
   PubMed Web of Science ®Google Scholar
• Klein M, Mann H, Vencovský J. Arthritis in idiopathic inflammatory myopathies. Curr Rheumatol Rep. 2019;21(12):70.
   PubMed Web of Science ®Google Scholar
• Gasparotto M, Gatto M, Saccon F, et al. Pulmonary involvement in antisynthetase syndrome. Curr Opin Rheumatol. 2019;31(6):603–610.
   PubMed Web of Science ®Google Scholar
• Olivier PA, de Paepe B, Aronica E, et al. Idiopathic inflammatory myopathy: interrater variability in muscle biopsy reading. Neurology. 2019;93(9):e889–e894.
   PubMed Web of Science ®Google Scholar
• Barba T, Mainbourg S, Nasser M, et al. Lung diseases in inflammatory myopathies. Semin Respir Crit Care Med. 2019;40(2):255–270.
   PubMed Web of Science ®Google Scholar
• Grainger AJ, Resnik CS. Arthritis. In: Hodler J, Kubik-Huch RA, von Schulthess GK, editors. Musculoskelet Dis 2021–2024: diagnostic imaging. New York City: Springer Cham: IDKD Springer Series; 2021. p. 149–168.
   Google Scholar
• Miller JB, Danoff SK, Bingham CO, et al. Sonographic findings from inflammatory arthritis due to antisynthetase syndrome. Clin Rheumatol. 2019;38(5):1477–1483.
   PubMed Web of Science ®Google Scholar
• Greco M, García De Yébenes MJ, Alarcón I, et al. Antisynthetase antibodies in clinical laboratories: the importance of clinical correlation and indirect immunofluorescence. Response to: comment on: ‘idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria’ by Greco et al.’ by Knitza et al. Ann Rheum Dis. 2020;79(7):e87.
   PubMed Web of Science ®Google Scholar
• Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev. 2014;13(4–5):367–371.
   PubMed Web of Science ®Google Scholar
• Greco M, García De Yébenes MJ, Alarcón I, et al. Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria. Ann Rheum Dis. 2019;78(9):1291–1292.
   PubMed Web of Science ®Google Scholar
• Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med. 2016;23(5):218–226.
   PubMedGoogle Scholar
• Cavagna T-A, Meloni  , et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med. 2019;8:2013.
   PubMed Web of Science ®Google Scholar
• Levi Y, Israeli-Shani L, Kuchuk M, et al. Rheumatological assessment is important for interstitial lung disease diagnosis. J Rheumatol. 2018;45(11):1509–1514.
   PubMed Web of Science ®Google Scholar
• Marco JL, Collins BF. Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol. 2020;34(4):101503.
   PubMed Web of Science ®Google Scholar
• Huapaya JA, Silhan L, Pinal-Fernandez I, et al. Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease. Chest. 2019;156(5):896–906.
   PubMed Web of Science ®Google Scholar
• Mecoli CA, Christopher-Stine L. Management of interstitial lung disease in patients with myositis specific autoantibodies. Curr Rheumatol Rep. 2018;20(5):27.
   PubMed Web of Science ®Google Scholar
• Labirua-Iturburu A, Selva-O’Callaghan A, Martínez-Gómez X, et al. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol. 2013;31:436–439.
   PubMed Web of Science ®Google Scholar
• Doyle TJ, Dhillon N, Madan R, et al. Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review. J Rheumatol. 2018;45(6):841–850.
   PubMed Web of Science ®Google Scholar
• Huapaya JA, Hallowell R, Silhan L, et al. Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease. Respir Med. 2019;154:6–11.
   PubMed Web of Science ®Google Scholar
• McGrath ER, Doughty CT, Amato AA. Autoimmune myopathies: updates on evaluation and treatment. Neurotherapeutics. 2018;15(4):976–994.
   PubMed Web of Science ®Google Scholar
• Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol. 2018;14(5):279–289.
   PubMed Web of Science ®Google Scholar
• Yamakawa H, Hagiwara E, Kitamura H, et al. Predictive factors for the long-term deterioration of pulmonary function in interstitial lung disease associated with anti-Aminoacyl-tRNA synthetase antibodies. Respiration. 2018;96(3):210–221.
   PubMed Web of Science ®Google Scholar
• Tanizawa K, Handa T, Nakashima R, et al. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respir Med. 2017;127:57–64.
   PubMed Web of Science ®Google Scholar
• Xu Q, Li QX, Bi FF, et al. The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies. Clin Rheumatol. 2021;40(2):613–624.
   PubMed Web of Science ®Google Scholar
• Baig S, Paik JJ. Inflammatory muscle disease – an update. Best Pract Res Clin Rheumatol. 2020;34(1):101484.
   PubMed Web of Science ®Google Scholar
• Albayda J, van Alfen N. Diagnostic value of muscle ultrasound for myopathies and myositis. Curr Rheumatol Rep. 2020;22(11):82.
   PubMed Web of Science ®Google Scholar
• Wasserman PL, Way A, Baig S, et al. MRI of myositis and other urgent muscle-related disorders. Emerg Radiol. 2021;28(2):409–421.
   PubMed Web of Science ®Google Scholar
• Lilleker JB, Roberts M, Diederichsen L. Cardiac involvement in inflammatory myopathies and inherited muscle diseases. Curr Opin Rheumatol. 2020;32(6):528–533.
   PubMed Web of Science ®Google Scholar
• Riddell V, Bagby S, McHugh N. Myositis autoantibodies: recent perspectives. Curr Opin Rheumatol. 2020;32(6):548–552.
   PubMed Web of Science ®Google Scholar
• Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280(1):8–23.
   PubMed Web of Science ®Google Scholar
• Bartoloni E, Gonzalez-Gay MA, Scirè C, et al. Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: results from a multicenter, international and retrospective study. Autoimmun Rev. 2017;16(3):253–257.
   PubMed Web of Science ®Google Scholar
• Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14(3):275–285.
   PubMed Web of Science ®Google Scholar